Wegovy, Zepbound and similar medications all lead to metabolic improvements, but scientists are starting to unpick the ...

Looking for successors to the blockbuster GLP-1 obesity drugs, companies like Novo Nordisk and Eli Lilly are testing amylin ...

The first trial of a GLP-1 in children 6-12 showed it was effective, but raises questions about whether the benefits of ...

Novo Nordisk's older weight-loss drug Saxenda helped children between the ages of 6 and under 12 reduce their body mass index ...

Novo Nordisk said on Wednesday its highly anticipated experimental weight-loss pill amycretin was safe and tolerable for ...

Eli Lilly has launched a new website-based access programme for some drugs ... access obesity drugs, including WW International (formerly known as Weight Watchers), Found, and Noom, adding to ...

The widespread use and enormous expense of blockbuster drugs like Wegovy are forcing state governments to make painful ...

The wave of new obesity drugs ... the FDA’s shortage list in 2022. They’ve been intermittently unavailable ever since. Shortages are a problem in part because these drugs must be taken consist ...

Morgan Stanley estimated that the global market for obesity drugs could increase by more than ... We've added you to our mailing list.

SYDNEY LUPKIN, BYLINE: Bill Coombs, who lives in Boston's South End, has lost 28 pounds so far on the obesity ... Drug Administration hasn't taken these drugs off its official shortage list.

But does this new version of the drug come with its own costs? Zepbound is the latest drug to join the growing list of anti-obesity medications ... denied access to the essential treatment and ...

The branded drugs ... adding their names to the growing list of companies providing telehealth weight loss management and access to trendy GLP-1 medications. Analysts forecast that the obesity ...